Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients with Immune Thrombocytopenia

Trial Profile

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients with Immune Thrombocytopenia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Kyowa Hakko Kirin China Pharmaceutical
  • Most Recent Events

    • 26 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top